Urinary and rectal toxicity profiles after permanent iodine-125 implant brachytherapy in Japanese men: Nationwide J-POPS multi-institutional prospective cohort study

Toshio Ohashi, Atsunori Yorozu, Shiro Saito, Nobumichi Tanaka, Norihisa Katayama, Shinsuke Kojima, Shinichiro Maruo, Takashi Kikuchi, Takushi Dokiya, Masanori Fukushima, Hidetoshi Yamanaka

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose To assess, in a nationwide multi-institutional cohort study begun in 2005 and in which 6927 subjects were enrolled by 2010, the urinary and rectal toxicity profiles of subjects who enrolled during the first 2 years, and evaluate the toxicity profiles for permanent seed implantation (PI) and a combination therapy with PI and external beam radiation therapy (EBRT). Methods and Materials Baseline data for 2339 subjects out of 2354 patients were available for the analyses. Toxicities were evaluated using the National Cancer Institute's Common Terminology Criteria for Adverse Events, and the International Prostate Symptom Scores were recorded prospectively until 36 months after radiation therapy. Results Grade 2+ acute urinary toxicities developed in 7.36% (172 of 2337) and grade 2+ acute rectal toxicities developed in 1.03% (24 of 2336) of the patients. Grade 2+ late urinary and rectal toxicities developed in 5.75% (133 of 2312) and 1.86% (43 of 2312) of the patients, respectively. A higher incidence of grade 2+ acute urinary toxicity occurred in the PI group than in the EBRT group (8.49% vs 3.66%; P<.01). Acute rectal toxicity outcomes were similar between the treatment groups. The 3-year cumulative incidence rates for grade 2+ late urinary toxicities were 6.04% versus 4.82% for the PI and the EBRT groups, respectively, with no significant differences between the treatment groups. The 3-year cumulative incidence rates for grade 2+ late rectal toxicities were 0.90% versus 5.01% (P<.01) for the PI and the EBRT groups, respectively. The mean of the postimplant International Prostate Symptom Score peaked at 3 months, but it decreased to a range that was within 2 points of the baseline score, which was observed in 1625 subjects (69.47%) at the 1-year follow-up assessment. Conclusions The acute urinary toxicities observed were acceptable given the frequency and retention, and the late rectal toxicities were more favorable than those of other studies.

Original languageEnglish
Pages (from-to)141-149
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Volume93
Issue number1
DOIs
Publication statusPublished - 2015 Sep 1

Fingerprint

iodine 125
Brachytherapy
toxicity
Iodine
Seeds
Cohort Studies
Radiotherapy
Prospective Studies
profiles
grade
seeds
radiation therapy
implantation
Prostate
Incidence
National Cancer Institute (U.S.)
Terminology
incidence
Therapeutics
terminology

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Urinary and rectal toxicity profiles after permanent iodine-125 implant brachytherapy in Japanese men : Nationwide J-POPS multi-institutional prospective cohort study. / Ohashi, Toshio; Yorozu, Atsunori; Saito, Shiro; Tanaka, Nobumichi; Katayama, Norihisa; Kojima, Shinsuke; Maruo, Shinichiro; Kikuchi, Takashi; Dokiya, Takushi; Fukushima, Masanori; Yamanaka, Hidetoshi.

In: International Journal of Radiation Oncology Biology Physics, Vol. 93, No. 1, 01.09.2015, p. 141-149.

Research output: Contribution to journalArticle

Ohashi, Toshio ; Yorozu, Atsunori ; Saito, Shiro ; Tanaka, Nobumichi ; Katayama, Norihisa ; Kojima, Shinsuke ; Maruo, Shinichiro ; Kikuchi, Takashi ; Dokiya, Takushi ; Fukushima, Masanori ; Yamanaka, Hidetoshi. / Urinary and rectal toxicity profiles after permanent iodine-125 implant brachytherapy in Japanese men : Nationwide J-POPS multi-institutional prospective cohort study. In: International Journal of Radiation Oncology Biology Physics. 2015 ; Vol. 93, No. 1. pp. 141-149.
@article{7fd5312cf4694335917bb5ccc0cbb9b6,
title = "Urinary and rectal toxicity profiles after permanent iodine-125 implant brachytherapy in Japanese men: Nationwide J-POPS multi-institutional prospective cohort study",
abstract = "Purpose To assess, in a nationwide multi-institutional cohort study begun in 2005 and in which 6927 subjects were enrolled by 2010, the urinary and rectal toxicity profiles of subjects who enrolled during the first 2 years, and evaluate the toxicity profiles for permanent seed implantation (PI) and a combination therapy with PI and external beam radiation therapy (EBRT). Methods and Materials Baseline data for 2339 subjects out of 2354 patients were available for the analyses. Toxicities were evaluated using the National Cancer Institute's Common Terminology Criteria for Adverse Events, and the International Prostate Symptom Scores were recorded prospectively until 36 months after radiation therapy. Results Grade 2+ acute urinary toxicities developed in 7.36{\%} (172 of 2337) and grade 2+ acute rectal toxicities developed in 1.03{\%} (24 of 2336) of the patients. Grade 2+ late urinary and rectal toxicities developed in 5.75{\%} (133 of 2312) and 1.86{\%} (43 of 2312) of the patients, respectively. A higher incidence of grade 2+ acute urinary toxicity occurred in the PI group than in the EBRT group (8.49{\%} vs 3.66{\%}; P<.01). Acute rectal toxicity outcomes were similar between the treatment groups. The 3-year cumulative incidence rates for grade 2+ late urinary toxicities were 6.04{\%} versus 4.82{\%} for the PI and the EBRT groups, respectively, with no significant differences between the treatment groups. The 3-year cumulative incidence rates for grade 2+ late rectal toxicities were 0.90{\%} versus 5.01{\%} (P<.01) for the PI and the EBRT groups, respectively. The mean of the postimplant International Prostate Symptom Score peaked at 3 months, but it decreased to a range that was within 2 points of the baseline score, which was observed in 1625 subjects (69.47{\%}) at the 1-year follow-up assessment. Conclusions The acute urinary toxicities observed were acceptable given the frequency and retention, and the late rectal toxicities were more favorable than those of other studies.",
author = "Toshio Ohashi and Atsunori Yorozu and Shiro Saito and Nobumichi Tanaka and Norihisa Katayama and Shinsuke Kojima and Shinichiro Maruo and Takashi Kikuchi and Takushi Dokiya and Masanori Fukushima and Hidetoshi Yamanaka",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.ijrobp.2015.05.014",
language = "English",
volume = "93",
pages = "141--149",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Urinary and rectal toxicity profiles after permanent iodine-125 implant brachytherapy in Japanese men

T2 - Nationwide J-POPS multi-institutional prospective cohort study

AU - Ohashi, Toshio

AU - Yorozu, Atsunori

AU - Saito, Shiro

AU - Tanaka, Nobumichi

AU - Katayama, Norihisa

AU - Kojima, Shinsuke

AU - Maruo, Shinichiro

AU - Kikuchi, Takashi

AU - Dokiya, Takushi

AU - Fukushima, Masanori

AU - Yamanaka, Hidetoshi

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Purpose To assess, in a nationwide multi-institutional cohort study begun in 2005 and in which 6927 subjects were enrolled by 2010, the urinary and rectal toxicity profiles of subjects who enrolled during the first 2 years, and evaluate the toxicity profiles for permanent seed implantation (PI) and a combination therapy with PI and external beam radiation therapy (EBRT). Methods and Materials Baseline data for 2339 subjects out of 2354 patients were available for the analyses. Toxicities were evaluated using the National Cancer Institute's Common Terminology Criteria for Adverse Events, and the International Prostate Symptom Scores were recorded prospectively until 36 months after radiation therapy. Results Grade 2+ acute urinary toxicities developed in 7.36% (172 of 2337) and grade 2+ acute rectal toxicities developed in 1.03% (24 of 2336) of the patients. Grade 2+ late urinary and rectal toxicities developed in 5.75% (133 of 2312) and 1.86% (43 of 2312) of the patients, respectively. A higher incidence of grade 2+ acute urinary toxicity occurred in the PI group than in the EBRT group (8.49% vs 3.66%; P<.01). Acute rectal toxicity outcomes were similar between the treatment groups. The 3-year cumulative incidence rates for grade 2+ late urinary toxicities were 6.04% versus 4.82% for the PI and the EBRT groups, respectively, with no significant differences between the treatment groups. The 3-year cumulative incidence rates for grade 2+ late rectal toxicities were 0.90% versus 5.01% (P<.01) for the PI and the EBRT groups, respectively. The mean of the postimplant International Prostate Symptom Score peaked at 3 months, but it decreased to a range that was within 2 points of the baseline score, which was observed in 1625 subjects (69.47%) at the 1-year follow-up assessment. Conclusions The acute urinary toxicities observed were acceptable given the frequency and retention, and the late rectal toxicities were more favorable than those of other studies.

AB - Purpose To assess, in a nationwide multi-institutional cohort study begun in 2005 and in which 6927 subjects were enrolled by 2010, the urinary and rectal toxicity profiles of subjects who enrolled during the first 2 years, and evaluate the toxicity profiles for permanent seed implantation (PI) and a combination therapy with PI and external beam radiation therapy (EBRT). Methods and Materials Baseline data for 2339 subjects out of 2354 patients were available for the analyses. Toxicities were evaluated using the National Cancer Institute's Common Terminology Criteria for Adverse Events, and the International Prostate Symptom Scores were recorded prospectively until 36 months after radiation therapy. Results Grade 2+ acute urinary toxicities developed in 7.36% (172 of 2337) and grade 2+ acute rectal toxicities developed in 1.03% (24 of 2336) of the patients. Grade 2+ late urinary and rectal toxicities developed in 5.75% (133 of 2312) and 1.86% (43 of 2312) of the patients, respectively. A higher incidence of grade 2+ acute urinary toxicity occurred in the PI group than in the EBRT group (8.49% vs 3.66%; P<.01). Acute rectal toxicity outcomes were similar between the treatment groups. The 3-year cumulative incidence rates for grade 2+ late urinary toxicities were 6.04% versus 4.82% for the PI and the EBRT groups, respectively, with no significant differences between the treatment groups. The 3-year cumulative incidence rates for grade 2+ late rectal toxicities were 0.90% versus 5.01% (P<.01) for the PI and the EBRT groups, respectively. The mean of the postimplant International Prostate Symptom Score peaked at 3 months, but it decreased to a range that was within 2 points of the baseline score, which was observed in 1625 subjects (69.47%) at the 1-year follow-up assessment. Conclusions The acute urinary toxicities observed were acceptable given the frequency and retention, and the late rectal toxicities were more favorable than those of other studies.

UR - http://www.scopus.com/inward/record.url?scp=84939434778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939434778&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2015.05.014

DO - 10.1016/j.ijrobp.2015.05.014

M3 - Article

C2 - 26279031

AN - SCOPUS:84939434778

VL - 93

SP - 141

EP - 149

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -